A Oneindia Venture
Get Updates
Get notified about market trends, financial advice, and investment tips!
Click it and Unblock the Notifications
Sensex
73,249.39
▼ -0.62%
Nifty
22,687.65
▼ -0.54%
22k Gold
₹ 13,235/gm
Silver
₹ 2,25,000/kg
Petrol
₹ 111.21
Diesel
₹ 97.83
LPG
₹ 941.50
Crude Oil
$ 111.91
USD
₹ 94.84
Sensex
73,249.39
▼ -0.62%
Nifty
22,687.65
▼ -0.54%
22k Gold
₹ 13,235/gm
Silver
₹ 2,25,000/kg
Petrol
₹ 111.21
Diesel
₹ 97.83
LPG
₹ 941.50
Crude Oil
$ 111.91
USD
₹ 94.84
Nippon India Pharma Fund - Direct Plan
3 Year Absolute Returns
25.43% ↑
NAV (₹) on 21 Oct 2026
162.94
1 Day NAV Change
-0.46%
Risk Level
Very High Risk
Rating
-
Nippon India Pharma Fund - Direct Plan is a Equity mutual fund categorized under Sector, offered by Nippon Life India Asset Management Ltd.. Launched on 01 Jan 2013, investors can start with a minimum ... Read more
NAV History
Fund Details
Min. SIP Amount
₹100
Inception Date
01 Jan 2013
Min. Lumpsum Amount
₹ 5,000
Fund Age
13 Yrs
AUM
₹ 9,166.40 Cr.
Benchmark
BSE Healthcare Total Return
Expense Ratio
1.00%
Scheme Type
Open Ended
Exit Load
1%
Returns Calculator
Investment amount per month
₹1,000
Over the past
Would have become
On total investment of
*Calculation based on past performance of this fund.
Asset Allocation
AUM
₹ 9,166.40 Cr
Equity
97.31%
Money Market & Cash
2.83%
Sector Holdings
| Sectors | Weightage |
|---|---|
| Pharmaceuticals | 77.01% |
| Hospitals & Medical Services | 19.41% |
| Treps/Reverse Repo | 2.81% |
| Chemicals - Speciality | 0.89% |
| Cash | 0.02% |
Stock Holdings
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.71% | ₹ 1,072.95 | Pharmaceuticals |
| Divi's Laboratories Limited | 7.10% | ₹ 651.11 | Pharmaceuticals |
| Lupin Limited | 6.17% | ₹ 565.21 | Pharmaceuticals |
| Cipla Limited | 6.01% | ₹ 551.19 | Pharmaceuticals |
| Dr. Reddy's Laboratories Limited | 5.45% | ₹ 499.33 | Pharmaceuticals |
| Apollo Hospitals Enterprise Limited | 4.89% | ₹ 448.12 | Hospitals & Medical Services |
| Mankind Pharma Limited | 4.38% | ₹ 401.50 | Pharmaceuticals |
| Sai Life Sciences Limited | 3.92% | ₹ 359.13 | Pharmaceuticals |
| Ajanta Pharma Limited | 3.61% | ₹ 330.91 | Pharmaceuticals |
| GlaxoSmithKline Pharmaceuticals Limited | 3.11% | ₹ 285.09 | Pharmaceuticals |
| IPCA Laboratories Limited | 2.87% | ₹ 262.99 | Pharmaceuticals |
| Triparty Repo | 2.81% | ₹ 257.79 | Others |
| Max Healthcare Institute Limited | 2.70% | ₹ 247.15 | Hospitals & Medical Services |
| Vijaya Diagnostic Centre Limited | 2.62% | ₹ 240.33 | Hospitals & Medical Services |
| Gland Pharma Limited | 2.53% | ₹ 232.11 | Pharmaceuticals |
| MedPlus Health Services Limited | 2.53% | ₹ 232.18 | Pharmaceuticals |
| Abbott India Limited | 2.32% | ₹ 213.06 | Pharmaceuticals |
| Thyrocare Technologies Limited | 2.24% | ₹ 205 | Hospitals & Medical Services |
| Piramal Pharma Limited | 2.24% | ₹ 205.22 | Pharmaceuticals |
| Dr. Lal Path Labs Limited | 2.17% | ₹ 198.81 | Hospitals & Medical Services |
| Alkem Laboratories Limited | 1.82% | ₹ 167.13 | Pharmaceuticals |
| Aurobindo Pharma Limited | 1.65% | ₹ 150.92 | Pharmaceuticals |
| Narayana Hrudayalaya Limited | 1.61% | ₹ 147.60 | Hospitals & Medical Services |
| Suraksha Diagnostic Limited | 1.51% | ₹ 138.48 | Hospitals & Medical Services |
| Syngene International Limited | 1.40% | ₹ 127.91 | Pharmaceuticals |
| Emcure Pharmaceuticals Limited | 1.36% | ₹ 124.53 | Pharmaceuticals |
| Pfizer Limited | 1.35% | ₹ 123.33 | Pharmaceuticals |
| Akums Drugs and Pharmaceuticals Limited | 1.21% | ₹ 110.63 | Pharmaceuticals |
| Anthem Biosciences Limited | 1.19% | ₹ 109.47 | Pharmaceuticals |
| Fortis Healthcare Limited | 1.13% | ₹ 103.65 | Hospitals & Medical Services |
| Biocon Limited | 1.01% | ₹ 92.73 | Pharmaceuticals |
| Sanofi India Limited | 1.00% | ₹ 91.79 | Pharmaceuticals |
| Sanofi Consumer Healthcare India Limited | 0.89% | ₹ 81.25 | Chemicals - Speciality |
| Molbio Diagnostics Limited | 0.54% | ₹ 49.78 | Hospitals & Medical Services |
| Indoco Remedies Limited | 0.48% | ₹ 43.96 | Pharmaceuticals |
| AstraZeneca Pharma India Limited | 0.42% | ₹ 38.70 | Pharmaceuticals |
| Concord Biotech Limited | 0.17% | ₹ 15.35 | Pharmaceuticals |
| Cash Margin - CCIL | 0.02% | ₹ 1.50 | Others |
Returns
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | 1.30% | -4.39% | -5.89% | 7.84% |
| Category returns | 3.14% | -1.22% | 1.10% | 18.59% |
Fund Objective
The primary investment objective of the scheme is to seek to generate continuous returns by investing in equity and equity related or fixed-income securities of Pharma and other associated companies.
AMC Details
Name
Nippon Life India Asset Management Ltd.
Date of Incorporation
30 Jun 1995
CEO
Mr. Sundeep Sikka
CIO
Mr. Amit Tripathi Mr. Sailesh Raj Bhan
Type
Foreign
Address
4th Floor, Tower A,
Peninsula Business Park,
Ganapatrao Kadam Marg,
Lower Parel (W), Mumbai, Maharashtra, India - 400013
Website
https://www.nipponindiamf.com
Email
Top Funds from Equity - Sectoral/Thematic
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹34.47 | 97.94% | 295.52% | 0.00% | ₹1,147 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹34.47 | 97.94% | 295.52% | 0.00% | ₹1,147 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹34.47 | 97.94% | 295.52% | 0.00% | ₹1,147 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹32.14 | 95.31% | 279.57% | 0.00% | ₹1,147 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹32.14 | 95.31% | 279.57% | 0.00% | ₹1,147 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹32.14 | 95.31% | 279.57% | 0.00% | ₹1,147 | 2.34% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹29.34 | 15.31% | 139.64% | 0.00% | ₹11,493 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹29.34 | 15.31% | 139.64% | 0.00% | ₹11,493 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹29.34 | 15.31% | 139.64% | 0.00% | ₹11,493 | 0.89% |
Very High
|
|
HDFC Defence Fund
Sector
Regular
|
₹28.27 | 14.21% | 132.02% | 0.00% | ₹11,493 | 1.79% |
Very High
|
Top Funds from Nippon Life India Asset Management Ltd.
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹34.47 | 97.94% | 295.52% | 0.00% | ₹1,147 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹34.47 | 97.94% | 295.52% | 0.00% | ₹1,147 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹34.47 | 97.94% | 295.52% | 0.00% | ₹1,147 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹32.14 | 95.31% | 279.57% | 0.00% | ₹1,147 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹32.14 | 95.31% | 279.57% | 0.00% | ₹1,147 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹32.14 | 95.31% | 279.57% | 0.00% | ₹1,147 | 2.34% |
Very High
|
|
Nippon India Silver ETF
ETF
Regular
|
₹195.90 | 28.85% | 176.10% | 0.00% | ₹31,196 | N/A |
Very High
|
|
Nippon India Silver ETF FOF - Direct Plan
Fund of Funds
Direct
|
₹31.07 | 30.03% | 171.12% | 0.00% | ₹4,354 | 0.22% |
Very High
|
|
Nippon India Silver ETF FOF - Direct Plan
Fund of Funds
Direct
|
₹31.07 | 30.03% | 171.12% | 0.00% | ₹4,354 | 0.22% |
Very High
|
|
Nippon India Silver ETF FOF - Direct Plan
Fund of Funds
Direct
|
₹31.07 | 30.03% | 171.12% | 0.00% | ₹4,354 | 0.22% |
Very High
|
FAQs
What is the current NAV of Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment?
The current Net Asset Value (NAV) of Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment is ₹162.94 as of 21 Oct 2026. NAV represents the per-unit market value of the fund and is updated daily based on the closing prices of the underlying securities.
What is the fund size (AUM) of Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment?
The Assets Under Management (AUM) of Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment is ₹9,166.40 Crores. AUM indicates the total market value of assets managed by the fund and reflects investor confidence and fund popularity.
What are the historical returns of Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment?
Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment has delivered returns of -4.39% (1 Year), 7.84% (3 Year), 7.17% (5 Year). Past performance does not guarantee future results, and investors should consider their risk appetite before investing.
What is the risk level of Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment?
Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment has a risk rating of 'Very High' as per the SEBI Riskometer. This indicates the fund is suitable for very aggressive investors comfortable with significant market volatility. Investors should align their investment choices with their personal risk tolerance and financial goals.
What is the minimum investment amount for Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment?
The minimum lumpsum investment required for Nippon India Pharma Fund - Direct Plan IDCW-Reinvestment is ₹5,000. The fund also offers SIP (Systematic Investment Plan) option starting from as low as ₹100, making it accessible for regular investments. This allows investors to start their mutual fund journey with a manageable amount.
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article
Top Mutual Fund House in India
Notifications
Settings
Clear Notifications
Notifications
Use the toggle to switch on notifications
-
Block for 8 hours
-
Block for 12 hours
-
Block for 24 hours
-
Don't block
Stay Informed.
Get news and videos anytime and anywhere.
Sign in with Google By signing in, you agree to our Terms and Privacy Policy
Gender
Select your Gender
- Male
- Female
- Others
Age
Select your Age Range
- Under 18
- 18 to 25
- 26 to 35
- 36 to 45
- 45 to 55
- 55+